These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 9399643)
1. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Walsh AB; Dhanasekaran M; Bar-Sagi D; Kumar CC Oncogene; 1997 Nov; 15(21):2553-60. PubMed ID: 9399643 [TBL] [Abstract][Full Text] [Related]
2. SCH 51344 inhibits ras transformation by a novel mechanism. Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559 [TBL] [Abstract][Full Text] [Related]
3. [Inhibition of RAS-transformation by SCH51344]. Kumar CC Gan To Kagaku Ryoho; 1997 Sep; 24(11):1503-11. PubMed ID: 9309148 [TBL] [Abstract][Full Text] [Related]
4. SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Kumar CC; Ohashi K; Nagata K; Walsh A; Bar-Sagi D; Mizuno K Ann N Y Acad Sci; 1999; 886():122-31. PubMed ID: 10667210 [TBL] [Abstract][Full Text] [Related]
5. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Xiao L; Lang W Cancer Res; 2000 Jan; 60(2):400-8. PubMed ID: 10667594 [TBL] [Abstract][Full Text] [Related]
6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018 [TBL] [Abstract][Full Text] [Related]
7. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Futamura M; Kamiya S; Tsukamoto M; Hirano A; Monden Y; Arakawa H; Nishimura S Oncogene; 2001 Oct; 20(46):6724-30. PubMed ID: 11709707 [TBL] [Abstract][Full Text] [Related]
8. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353 [TBL] [Abstract][Full Text] [Related]
9. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling. Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703 [TBL] [Abstract][Full Text] [Related]
11. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. Murphy GA; Solski PA; Jillian SA; Pérez de la Ossa P; D'Eustachio P; Der CJ; Rush MG Oncogene; 1999 Jul; 18(26):3831-45. PubMed ID: 10445846 [TBL] [Abstract][Full Text] [Related]
12. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Ulkü AS; Schäfer R; Der CJ Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291 [TBL] [Abstract][Full Text] [Related]
13. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. He H; Hirokawa Y; Levitzki A; Maruta H Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144 [TBL] [Abstract][Full Text] [Related]
14. TC21 and Ras share indistinguishable transforming and differentiating activities. Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735 [TBL] [Abstract][Full Text] [Related]
15. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Lambert JM; Lambert QT; Reuther GW; Malliri A; Siderovski DP; Sondek J; Collard JG; Der CJ Nat Cell Biol; 2002 Aug; 4(8):621-5. PubMed ID: 12134164 [TBL] [Abstract][Full Text] [Related]
16. An essential role for Rac in Ras transformation. Qiu RG; Chen J; Kirn D; McCormick F; Symons M Nature; 1995 Mar; 374(6521):457-9. PubMed ID: 7700355 [TBL] [Abstract][Full Text] [Related]
17. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. Zohar M; Teramoto H; Katz BZ; Yamada KM; Gutkind JS Oncogene; 1998 Aug; 17(8):991-8. PubMed ID: 9747878 [TBL] [Abstract][Full Text] [Related]
19. Rac is required for v-Abl tyrosine kinase to activate mitogenesis. Renshaw MW; Lea-Chou E; Wang JY Curr Biol; 1996 Jan; 6(1):76-83. PubMed ID: 8805224 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445. Tikoo A; Cutler H; Lo SH; Chen LB; Maruta H Cancer J Sci Am; 1999; 5(5):293-300. PubMed ID: 10526670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]